|
SC4MOL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.75870034885884E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.09190001274362E-09 |
| Normal-vs-Stage2 |
3.275600E-02 |
| Normal-vs-Stage3 |
3.69839999736499E-08 |
| Normal-vs-Stage4 |
1.81109999997098E-07 |
| Stage1-vs-Stage2 |
2.686400E-01 |
| Stage1-vs-Stage3 |
5.667400E-01 |
| Stage1-vs-Stage4 |
5.800600E-01 |
| Stage2-vs-Stage3 |
1.752010E-01 |
| Stage2-vs-Stage4 |
1.824570E-01 |
| Stage3-vs-Stage4 |
9.975800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.32669994382206E-10 |
| Normal-vs-AfricanAmerican |
5.237800E-03 |
| Normal-vs-Asian |
2.08530000000984E-06 |
| Caucasian-vs-AfricanAmerican |
6.418000E-01 |
| Caucasian-vs-Asian |
8.742600E-01 |
| AfricanAmerican-vs-Asian |
7.127000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.24869999998489E-06 |
| Normal-vs-Female |
4.00499966524137E-10 |
| Male-vs-Female |
2.310400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.6160999467304E-09 |
| Normal-vs-Age(41-60Yrs) |
1.12939999574735E-08 |
| Normal-vs-Age(61-80Yrs) |
5.355300E-04 |
| Normal-vs-Age(81-100Yrs) |
4.179500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.879000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.334400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.969800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.138400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.992800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.549400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.822400E-01 |
| Classical-VS-Follicular |
<1E-12 |
| Classical-VS-Other |
2.036000E-01 |
| Classical-VS-Normal |
5.42899059041702E-14 |
| Tall-VS-Follicular |
2.61309995863712E-09 |
| Tall-VS-Other |
2.363200E-01 |
| Tall-VS-Normal |
1.4387000479843E-09 |
| Follicular-VS-Other |
1.072960E-01 |
| Follicular-VS-Normal |
5.518600E-01 |
| Other-VS-Normal |
2.935400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.36139999999696E-05 |
| Normal-vs-N1 |
1.79842999999957E-05 |
| N0-vs-N1 |
1.775790E-01 |
|
|
